A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.

Pain Treatments surged 11.5% as management explores strategic alternatives.

Bioventus stock has delivered strong share price gains over the past few years, yet current valuation checks still suggest it screens as relatively cheap on several metrics. That combination of a big historical return with an apparently supportive valuation is what current and prospective shareholders are trying to interpret. Over the last 3 years Bioventus has returned about 198%, which puts a spotlight on whether the current price already reflects much of the good news that investors...

In early August 2026, Bioventus Inc. reported second-quarter sales of US$153.21 million and net income of US$33.44 million, sharply higher than a year earlier, and reaffirmed its full-year 2026 net sales guidance of US$600 million to US$610 million. The combination of rising sales, a substantial jump in earnings per share, and management’s confidence in its 2026 outlook highlights improved operational performance and profitability momentum across Bioventus’ portfolio. Now we’ll examine how...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Moby summary of Bioventus Inc.'s Q2 2026 earnings call

Bioventus Inc (BVS) delivers solid Q2 with 4% revenue growth, reduces leverage below 2x, and announces strategic review following unsolicited acquisition interest.

Bioventus (NASDAQ:BVS) reported second-quarter 2026 revenue growth of 4% and reiterated its full-year financial outlook, citing double-digit expansion in its Pain Treatments business, continued debt reduction and increased investment in platelet-rich plasma, peripheral nerve stimulation, Ultrasonics

Bioventus (BVS) delivered earnings and revenue surprises of 0.00% and -1.16%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Relay Therapeutics (RLAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bioventus (BVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here is how Bioventus (BVS) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

The consensus price target hints at a 28.9% upside potential for Bioventus (BVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Bioventus (BVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.